Ligand Pharmaceuticals Incorporated (LGND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ligand Pharmaceuticals Incorporated (LGND) Stock Forecast
Analysts expect Ligand Pharmaceuticals (LGND) to earn $9.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $291.72M. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.73, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 27.3% |
| Buy | 8 | 72.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 24.7% and revenue estimates rise 31.7%.
- Fiscal year ending Dec 31, 2026
- $9.58
- EPS consensus, revenue $291.72M
- Fiscal year ending Dec 31, 2027
- $11.95
- EPS consensus, revenue $384.11M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $9.58 | $9.25 to $9.74 | 10 | $291.72M | $285.80M to $297.27M | 10 |
| Dec 31, 2027 | $11.95 | $10.01 to $13.12 | 9 | $384.11M | $355.10M to $403.13M | 9 |
Quarterly Estimates
The EPS consensus falls from $2.97 for the quarter ending Dec 31, 2026 to $2.36 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.97 | $2.38 to $3.17 | 14 | $99.62M | $87.81M to $109.32M | 13 |
| Mar 31, 2027 | $2.36 | $2.31 to $2.41 | 2 | $76.14M | $76.14M to $76.14M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.8% from $9.32.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $9.58 | $9.52 | $9.31 | $9.32 | $9.32 | +2.8% |
| Fiscal year ending Dec 31, 2027 | $11.95 | $12.20 | $11.95 | $11.93 | $11.97 | -0.1% |
| Quarter ending Mar 31, 2027 | $2.36 | $2.31 | $2.30 | $2.30 | $2.30 | +2.6% |
Frequently Asked Questions About LGND
What is the LGND stock forecast?
Consensus analyst estimates put Ligand Pharmaceuticals's EPS at $9.58 for the fiscal year ending Dec 31, 2026, on revenue of $291.72M. The consensus rating from 11 analysts is Buy.
How do analysts rate LGND stock?
Of 11 analysts covering Ligand Pharmaceuticals, 3 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LGND next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.58, with estimates from $9.25 to $9.74 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.95, with estimates from $10.01 to $13.12 from 9 analysts.
What revenue do analysts expect from Ligand Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $291.72M, with estimates from $285.80M to $297.27M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $384.11M, with estimates from $355.10M to $403.13M.
How many analysts cover LGND?
11 analysts rate Ligand Pharmaceuticals stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LGND pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors